Frontier Medicines raises $80M, enters clinic and eyes potential IPO in Q4 or early 2025
Frontier Medicines, a bicoastal biotech creating covalent small molecules, has secured $80 million in Series C funds and dosed the first patient in its initial clinical trial as it looks to create a next-generation KRAS treatment behind Amgen and Bristol Myers Squibb-acquired Mirati.
The South San Francisco and Boston biotech has had crossover investors since its Series A, giving the 100-person startup some wiggle room to go public when the time and market conditions are right, CEO Chris Varma told Endpoints News in an interview. With its first batch of clinical data expected by year’s end, Frontier could chart an IPO later this year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
